San Diego-primarily based Viking Therapeutics marked by itself as a serious competitor in the weight loss drug market in February immediately after revealing promising data from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as in